---
schema_version: "secwatch.filing_event.v1"
accession: "0001040130-26-000068"
form_type: "8-K"
ticker: "PETS"
cik: "0001040130"
company_name: "PETMED EXPRESS INC"
filed_at: "2026-11-10T21:17:45+00:00"
generated_at: "2026-11-10T21:19:16.786721+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.62
calibrated_materiality_score: 0.62
confidence: "high"
source: SEC EDGAR
---

# PetMeds Q2 net sales fall 19.4% to $35.8M; net loss narrows to $6.4M ($0.31/sh)

## Summary
- Net sales of $35.8M vs $44.4M a year ago, down 19.4%, driven by lower prescription medication sales and higher consumer promotional usage.
- Net loss of $6.4M, or $(0.31) per diluted share, versus a net loss of $8.5M, or $(0.41) per diluted share, in the prior-year quarter.
- Adjusted EBITDA was $(3.6)M, worse than $(2.3)M a year ago; lower G&A and advertising spend was offset by weaker gross profit and lower manufacturer rebates.
- CEO Jeff Willard said operations are "stabilized"; customer acquisition cost fell 32% YoY, with focus on repositioning the brand and improving retention.
- No financial guidance was provided in the release; earnings webcast scheduled for 4:30pm Eastern on November 10, 2026.

## SEC filing metadata
- accession: 0001040130-26-000068
- form_type: 8-K
- ticker: PETS
- cik: 0001040130
- company_name: PETMED EXPRESS INC
- filed_at: 2026-11-10T21:17:45+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.62
- calibrated_materiality_score: 0.62
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1040130/000104013026000068/0001040130-26-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1040130/000104013026000068/pets-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001040130-26-000068
- JSON: https://secwatch.observer/filing/0001040130-26-000068.json
- Plain text: https://secwatch.observer/filing/0001040130-26-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.